Oncolytics Biotech — Corporate Update (December 2012)

4 slides from Oncolytics Biotech's corporate update, Dec 13, 2012

Slide 1: Phase 3 Clinical Update Conference Call
Phase 3 Clinical Update Conference Call December 13, 2012
Slide 2: Forward Looking Statements
Forward Looking Statements Today’s presentation contains certain forward looking statements relating to the company’s financial results, business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations
Slide 3: Percentage Change in Metastatic Lesions at First Post-Treatment Scan (Control vs. Test)
Figure 1: Percentage Change in Metastatic Lesions at First Post-Treatment Scan (Control vs. Test) 100.00% 80.00% 60.00% Percent Change Target Lesions 40.00% 20.00% Control 0.00% 0 0.2 0.4 0.6 0.8 1 1.2 Test -20.00% -40.00% -60.00% -80.00% -100.00% p=0.03
Slide 4: Percentage Change in Test Arm Lesions at First Post-Treatment Scan
Figure 2: Percentage Change in Test Arm Lesions at First Post-Treatment Scan (Loco-Regional vs. Metastatic) 100.00% 80.00% 60.00% Percent Change Target Lesions 40.00% 20.00% Test (Loco-Regional) 0.00% 0 0.2 0.4 0.6 0.8 1 1.2 Test (Metastatic) -20.00% -40.00% -60.00% -80.00% -100.00% p=0.13